Recent And Upcoming FDA Advisory Committees
Executive Summary
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
Higher Naloxone Doses Narrowly Favored By FDA Panel
Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.
Cempra's Solithromycin On Track To Enter Generic, But Resistant, CABP Market
FDA schedules November advisory committee for Cempra's first-in-class antibiotic for community-acquired bacterial pneumonia.
ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.